TAOX
vs
S&P 500
TAOX
S&P 500
Over the past 12 months, TAOX has significantly outperformed S&P 500, delivering a return of +32% compared to the S&P 500's +12% growth.
Stocks Performance
TAOX vs S&P 500
Performance Gap
TAOX vs S&P 500
Performance By Year
TAOX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TAO Synergies Inc
Glance View
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm's differentiated cryptocurrency treasury strategy is centered exclusively on the acquisition of TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI.
